28 recruiting, 20 active not recruiting, 15 terminated, 11 completed. 51 Phase 2, 25 Phase 1, 8 Phase 3, 2 Early Phase 1, 2 Not applicable.
Follow Stage IVB Prostate Cancer AJCC v8: new trials by email Literature Review of Stage IVB Prostate Cancer AJCC v8 trials Research Report on Stage IVB Prostate Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-12-01 | 2026-10-15 |
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan - Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2026-11-01 | 2026-10-16 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2026-03-31 | 2026-10-02 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-03-06 | 2026-04-20 |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial Androgen Therapy, Apalutamide, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1260 | 2025-12-01 | 2026-10-02 |
| Addressing Health Literacy With a Tailored Survivorship Care Plan Educational Intervention, Interview, Questionnaire Administration - Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Not applicable | Recruiting | Emory University | 150 | 2025-11-07 | 2026-09-30 |
| Imaging of Solid Tumors Using 18F-TRX 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Rahul Aggarwal | 56 | 2025-07-03 | 2026-07-23 |
| Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 51 | 2025-04-29 | 2026-07-07 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 3 | 2024-12-19 | 2026-08-07 |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body Biospecimen Collection, Bone Scan, Cabazitaxel - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 3 | Recruiting | SWOG Cancer Research Network | 528 | 2024-11-27 | 2026-01-22 |
| Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 48 | 2024-11-26 | 2026-08-11 |
| PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 21 | 2024-10-09 | 2026-08-21 |
Showing 20 of 86. Sign in to see all of them.
Prostatic Neoplasms (86) · Neoplasm Metastasis (6) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Ovarian Neoplasms (5) · Carcinoma, Transitional Cell (3) · Lung Neoplasms (3) · Urogenital Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Clear-cell metastatic renal cell carcinoma (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2)
Genital Diseases (86) · Genital Diseases, Male (86) · Genital Neoplasms, Male (86) · Male Urogenital Diseases (86) · Neoplasms by Site (86) · Prostatic Diseases (86) · Urogenital Diseases (86) · Neoplasms (85) · Urogenital Neoplasms (83) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Neoplastic Processes (7) · Digestive System Diseases (6)
Magnetic Resonance Spectroscopy (41) · Specimen Handling (35) · Biopsy (14) · Pluvicto (13) · enzalutamide (12) · gallium 68 PSMA-11 (12) · Abiraterone Acetate (11) · 68Ga-DKFZ-PSMA-11 (10) · Prednisone (10) · X-Rays (10) · deltacortene (9) · prednylidene (9) · Glutamate Carboxypeptidase II (8) · Leuprolide (8) · Photons (7)
M.D. Anderson Cancer Center (13) · National Cancer Institute (NCI) (11) · Jonsson Comprehensive Cancer Center (8) · University of Washington (8) · Mayo Clinic (7) · City of Hope Medical Center (5) · Alliance for Clinical Trials in Oncology (4) · Fred Hutchinson Cancer Center (4) · Roswell Park Cancer Institute (4) · Emory University (3) · Rahul Aggarwal (3) · ECOG-ACRIN Cancer Research Group (2) · Northwestern University (2) · SWOG Cancer Research Network (2) · University of Michigan Rogel Cancer Center (2)
United States (83) · Puerto Rico (3) · Canada (1) · Chile (1) · Colombia (1) · Mexico (1) · Switzerland (1)
Michael Schweizer (4) · Paul Corn (3) · Amar Kishan (2) · Gurkamal Chatta (2) · Jeremie Calais (2) · Jeremie Calais, MD (2) · Michael Schweizer, MD (2) · Rahul Aggarwal, MD (2) · Rosa Nadal Rios, MD, PhD (2) · Tanya B Dorff (2) · Zin W Myint (2) · Alex Chehrazi-Raffle, MD (1) · Alison M Schram (1) · Amar Kishan, MD (1) · Ana Aparicio (1)
PMID 41698328, PMID 33602654, PMID 34663638, PMID 35031545, PMID 35405009, PMID 35428207, PMID 36210299, PMID 36351402, PMID 37902861, PMID 38421243, PMID 38494380, PMID 38867077, PMID 39136560, PMID 39254446, PMID 39420060, PMID 39503807, PMID 40139261, PMID 40377420, PMID 40939237, PMID 41223345, PMID 41315064, PMID 41646361, PMID 41679923, PMID 41785440
P30CA033572 (4), P50CA097186 (4), P30CA138292 (3), P30CA060553 (2), U10CA180820 (2), U10CA180821 (2), U10CA180888 (2), UM1CA186689 (2), UM1CA186691 (2), UM1CA186712 (2), P30CA022453 (1), P30CA042014 (1), R01CA289631 (1), R01MH115043 (1), R37CA286450 (1)